Non-Small-Cell Lung Cancer – Unmet Need – Detailed, Expanded Analysis: EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC (US/EU)
Approximately 20% of Western patients with nonsquamous non-small-cell lung cancer (NSCLC) present with EGFR mutations, creating a market for targeted and personalized treatments. Although the market for EGFR-mutation-positive metastatic nonsquamous NSCLC patients is dominated by EGFR tyrosine kinase inhibitors (TKIs), most notably Tagrisso (AstraZeneca), there remains a strong need for drugs offering improved overall survival and less toxicity. Additional drugs targeting rare EGFR mutations, such as Rybrevant (Janssen) and Exkivity (Takeda), are also needed. Acquired resistance to targeted therapies creates an additional need for novel treatments and optimization of treatment sequencing.
QUESTIONS ANSWERED
- Which attributes most influence prescribers’ decisions for EGFR mutation-positive metastatic nonsquamous NSCLC?
- How do key current therapies, such as EGFR TKIs, perform on key treatment drivers and goals for this patient population?
- What are the prevailing areas of unmet need and hidden opportunities in the treatment of this patient population?
- What trade-offs across different clinical attributes and price are acceptable to surveyed medical oncologists for a hypothetical new first-line treatment for EGFR mutation-positive metastatic nonsquamous NSCLC?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 34 European medical oncologists fielded in May 2023
Key companies: AstraZeneca, Boehringer Ingelheim, Pfizer, Janssen, Merck & Co., Roche / Genentech
Key drugs: Tagrisso, Gilotrif, Vizimpro, Rybrevant, Tarceva (erlotinib), bevacizumab + paclitaxel + carboplatin
Table of contents
- Non-Small-Cell Lung Cancer - Unmet Need - Detailed, Expanded Analysis: EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC (US/EU)
- Executive summary
- Unmet Need - EGFR-mutation-positive metastatic nonsquamous NSCLC - Executive Summary - August 2023
- Introduction
- Overview
- Methodology
- Rationale for treatment drivers and goals selection
- Rationale for drug selection
- Products / regimens for EGFR-mutation-positive metastatic nonsquamous NSCLC and rationale for drug selection
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed medical oncologists prescribing decisions in EGFR-mutation-positive metastatic nonsquamous NSCLC
- Importance of efficacy attributes to prescribing decisions in EGFR-mutation-positive metastatic nonsquamous NSCLC: United States
- Importance of efficacy attributes to prescribing decisions in EGFR-mutation-positive metastatic nonsquamous NSCLC: Europe
- Importance of safety and tolerability attributes to prescribing decisions in EGFR-mutation-positive metastatic nonsquamous NSCLC: United States
- Importance of safety and tolerability attributes to prescribing decisions in EGFR-mutation-positive metastatic nonsquamous NSCLC: Europe
- Importance of convenience of administration attributes to prescribing decisions in EGFR-mutation-positive metastatic nonsquamous NSCLC: United States
- Importance of convenience of administration attributes to prescribing decisions in EGFR-mutation-positive metastatic nonsquamous NSCLC: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in EGFR-mutation-positive metastatic nonsquamous NSCLC: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in EGFR-mutation-positive metastatic nonsquamous NSCLC: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for EGFR-mutation-positive metastatic nonsquamous NSCLC: United States
- Overall performance of key therapies for EGFR-mutation-positive metastatic nonsquamous NSCLC: Europe
- Mean overall performance of key therapies for EGFR-mutation-positive metastatic nonsquamous NSCLC: United States and Europe
- Relative performance of key therapies for EGFR-mutation-positive metastatic nonsquamous NSCLC across select efficacy attributes: United States
- Relative performance of key therapies for EGFR-mutation-positive metastatic nonsquamous NSCLC across select efficacy attributes: Europe
- Relative performance of key therapies for EGFR-mutation-positive metastatic nonsquamous NSCLC across select safety and tolerability attributes: United States
- Relative performance of key therapies for EGFR-mutation-positive metastatic nonsquamous NSCLC across select safety and tolerability attributes: Europe
- Relative performance of key therapies for EGFR-mutation-positive metastatic nonsquamous NSCLC across select convenience of administration attributes: United States
- Relative performance of key therapies for EGFR-mutation-positive metastatic nonsquamous NSCLC across select convenience of administration attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in EGFR-mutation-positive metastatic nonsquamous NSCLC
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for EGFR-mutation-positive metastatic nonsquamous NSCLC on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed medical oncologists' satisfaction with the performance of key therapies for EGFR-mutation-positive metastatic nonsquamous NSCLC on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key efficacy attributes in EGFR-mutation-positive metastatic nonsquamous NSCLC: United States
- Surveyed medical oncologists' ascribed level of unmet need across key efficacy attributes in EGFR-mutation-positive metastatic nonsquamous NSCLC: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in EGFR-mutation-positive metastatic nonsquamous NSCLC: United States
- Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in EGFR-mutation-positive metastatic nonsquamous NSCLC: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in EGFR-mutation-positive metastatic nonsquamous NSCLC: United States
- Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in EGFR-mutation-positive metastatic nonsquamous NSCLC: Europe
- Key findings: unmet need in EGFR-mutation-positive metastatic nonsquamous NSCLC and related indications
- Surveyed medical oncologists' ascribed level of unmet need in EGFR-mutation-positive metastatic nonsquamous NSCLC and related indications: United States
- Surveyed medical oncologists' ascribed level of unmet need in EGFR-mutation-positive metastatic nonsquamous NSCLC and related indications: Europe
- Opportunity analysis
- Areas of opportunity in the EGFR-mutation-positive metastatic nonsquamous NSCLC market and emerging therapy insights
- Opportunity: a novel therapy that can extend overall survival
- Opportunity: a novel therapy that improves progression-free survival
- Opportunity: a novel therapy that has a better safety and tolerability profile
- Areas of opportunity in the EGFR-mutation-positive metastatic nonsquamous NSCLC market and emerging therapy insights
- Target product profiles
- Assessing drug development opportunities
- Target product profile methodology
- Attributes and attribute levels
- Attributes of key current and late-phase emerging therapies for EGFR-positive metastatic nonsquamous NSCLC
- Assigned prohibitions for the conjoint module
- Attribute importance and part-worth utilities
- EGFR-positive metastatic nonsquamous NSCLC target product profile: attribute importance
- Median overall survival (months)
- Median progression-free survival (months)
- Objective response rate (% of patients)
- Incidence of any grade diarrhea (% of patients)
- Incidence of grade 3/4 toxicities (% of patients)
- Incidence of any grade rash (% of patients)
- Price per 28-day cycle
- Conjoint analysis-based simulation of a market scenario
- EGFR-mutation-positive metastatic nonsquamous NSCLC market simulation: share of preference of target product profiles included in the market scenario
- EGFR-mutation-positive metastatic nonsquamous NSCLC market simulation: likelihood to prescribe of target product profiles included in the market scenario
- EGFR-mutation-positive metastatic nonsquamous NSCLC market simulation: target product profiles included in the market scenario
- Appendix
- Key abbreviations
- Bibliography
- Executive summary
Vandana Singh, M.Pharm., is an associate analyst on the Oncology team at Clarivate. Previously, she was a business analyst in digital marketing at Iquanti in Bangalore. She also conducted competitive intelligence, forecasting, and pipeline analysis at WNS in Noida. She obtained her master’s degree in pharmacology from the University of Delhi.
